Adipotide (FTPP)

Research-Grade

Adipotide, formally designated FTPP (Fat-Targeted Proapoptotic Peptide), is a chimeric peptidomimetic developed at the University of Texas MD Anderson Cancer Center by Dr. Wadih Arap and Dr. Renata Pasqualini. It consists of two functional domains joined in a single sequence: a targeting motif (CKGGRAKDC) that binds prohibitin on the luminal surface of blood vessels supplying white adipose tissue, and a proapoptotic domain (D(KLAKLAK)2) composed of D-amino acids that disrupts mitochondrial membranes upon internalization. The net effect is selective destruction of the vasculature feeding white fat depots, causing ischemic death of the adipose tissue itself. The landmark 2011 study in Science Translational Medicine demonstrated remarkable efficacy in obese rhesus monkeys. Over a 28-day treatment course of daily subcutaneous injections, treated monkeys lost an average of 11% of body weight and showed approximately 39% reduction in abdominal adiposity as measured by MRI. Body mass index decreased significantly, and insulin resistance improved. The fat loss was rapid and primarily targeted visceral and subcutaneous white adipose tissue. Notably, the weight loss occurred without enforced caloric restriction. However, the study also revealed significant safety concerns. Treated monkeys showed reversible renal toxicity, likely due to prohibitin expression on renal proximal tubule epithelium. Dehydration was observed and required careful fluid management. The proapoptotic mechanism is inherently aggressive — destroying blood vessels is not a physiological fat-loss pathway, and off-target vascular damage remains a major concern for any potential human application. As of 2026, no human clinical trials of adipotide have been conducted or registered. The compound remains firmly in the preclinical research phase. Its dramatic primate results have generated substantial interest in the peptide research community, but the gap between an obese monkey study and safe human therapeutics is vast. Researchers continue to explore whether the targeting specificity can be improved and the renal toxicity mitigated, but no timeline for human trials has been announced.